Mycenax Biotech has announced a strategic alliance with Spera Pharma to bring together the complementary strengths of both companies to deliver a comprehensive solution for Antibody-Drug Conjugates (ADCs) and bioconjugates, covering linker/payload synthesis, drug substance production, formulation and aseptic fill-finish.

The alliance aims to accelerate time-to-market for biopharmaceutical companies by offering an integrated and cost-effective ADC development and manufacturing platform. By leveraging Mycenax's end-to-end biologics capabilities with Krisan Biotech and Spera Pharma's CMC expertise—particularly in high-potent fill-finish services for ADCs, the partnership delivers a one-stop solution tailored to the needs of global clients.

Together, Mycenax and Spera Pharma offer an end-to-end development and manufacturing solution. This empowers global ADC developers with speed, flexibility and technical excellence.